Postoperative management of patients with endometriosis
Abstract
Aim: to assess the effectiveness of using dienogest in combination with postoperative interventions in patients with endometriosis.
Materials and methods. There were enrolled 102 patients with signs of external endometriosis underwent examination and surgical treatment, subdivided into 2 groups: 67 – main group (after surgical treatment, received dienogest 2 mg/day for 6 months), 35 – comparison group received no hormone therapy in the postoperative period. Surgical treatment included removal of endometrioid ovarian cysts, endometriosis foci on the pelvic peritoneum and sacral uterine ligaments. Course of the early postoperative period (up to 1 month after the intervention) as well as the long-term dynamics of the disease manifestations (3, 6, 12 and 15 months later) were assessed.
Results. Dienogest was administered after surgical treatment due to endometriosis that reduced the severity of dyspareunia and intensity of chronic pelvic pain by 3.5- and 2-fold, respectively. The probability of achieving control over uterine bleeding 6 month after the onset of treatment due to endometriosis manifested with metrorrhagia showed that combination treatment (consisting of dienogest) was 3.19-fold higher compared to surgical treatment alone (OR = 3.19; 95 % CI = 1.70–11,0; p < 0,05). Recovery of normal menstrual cycle in 63 (94.0%) women of the main group was established 1.5–2 months after completing of hormonal treatment, while in the comparison group pain and dysmenorrhea relapsed in some patients at the 6-month follow-up. Decreased libido as a side effect in patients who treated with dienogest was observed in 2 (3.0 %) women.
Conclusion. Dienogest was highly effective in the combination treatment of patients with verified endometriosis that resulted in reduced severity of pain and metrorrhagia. The drug was featured by low level of side effects. Thus, a combination treatment of endometriosis containing dienogest at a dose of 2 mg/day applied during postoperative period allows to reduce the severity of the disease clinical manifestations and improve treatment outcome.
About the Authors
Ju. E. Dobrokhotova
Russian National Research Medical University named after N. I. Pirogov, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Julia E. Dobrokhotova – MD, Dr Sci Med, Professor, Head of Department of Obstetrics and Gynecology, Faculty of Medicine
1 Ostrovityanova Str., Moscow 117997
D. M. Kalimatova
Russian National Research Medical University named after N. I. Pirogov, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Donna M. Kalimatova – MD, PhD, Associate Professor, Department of Obstetrics and Gynecology, Faculty of Medicine
1 Ostrovityanova Str., Moscow 117997
I. Yu. Ilyina
Russian National Research Medical University named after N. I. Pirogov, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Irina Yu. Ilyina – MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Faculty of Medicine
1 Ostrovityanova Str., Moscow 117997
References
1. Unanian A. L., Sidorova I.S., Nikonets A.D. et al. Dysmenorrhea, endometriosis, adenomyosis: clinical and pathogenetic relationships. [Dismenoreya, endometrioz, adenomioz: kliniko-patogeneticheskie vzaimootnosheniya]. Ginekologiya. 2018;20(1):9–15. (In Russ.).
2. Saprykina L.V., Dobrokhotova Yu.E., Saprykina O.A. Endometriosis: a pathogenetically justified hormone therapy. [Endometrioz: gormonal'naya terapiya s pozicij patogeneza]. Effektivnaya farmakoterapiya. 2015;(25):42–7. (In Russ.).
3. Dobrokhotova Yu.E., Ozerova R.I., Mandrykina Zh.A., Rora L.S. Some aspects of the etiology and pathogenesis of embryonic depletions in the first trimester of gestation. [Nekotorye aspekty etiologii i patogeneza embrional'nyh poter' v I trimestre gestacii]. Rossijskij vestnik akushera-ginekologa. 2008;8(5):15–8. (In Russ.).
4. Korobkova EA, Gordienko EV Dienogest and genital endometriosis. [Dienogest i genital’nyj endometrioz]. Universitetskaya klinika. 2017;(3–2):101–3. (In Russ.).
5. Suardika A., Astawa Pemayun T.G. New insights on the pathogenesis of endometriosis and novel non-surgical therapies. J Turk Ger Gynecol Assoc. 2018;19(3):158–64. DOI: 10.4274/jtgga.2018.0090.
6. Yarmolinskaya M. I., Florova M.S. The possibility of treatment with dienogest 2 mg in patients with genital endometriosis. [Vozmozhnosti terapii dienogestom 2 mg u bol’nyh naruzhnym genital’nym endometriozom]. Problemy reprodukcii. 2017;23(1):70–9. (In Russ.). DOI: 10.17116/repro201723170-79.
7. Berlanda N., Somigliana E., Frattaruolo M.P. et al. Surgery versus hormonal therapy for deep endometriosis: is it a choice of the physician? Eur J Obstet Gynecol Reprod Biol. 2017;209:67–71. DOI: 10.1016/j.ejogrb.2016.07.513.
8. Kalinkina O.B., Tezikov Yu.V., Lipatov I.S. et al. Long-term use of dienogest for the treatment of endometriosis. [Dlitel’noe primenenie dienogesta dlya lecheniya endometrioza]. Aspirantskij vestnik Povolzh’ya. 2017;(1–2):18–23. (In Russ.).
9. Balan V. E., Orlova S. A., Titchenko Yu.P. et al. Safety of prolonged use of dienogest (Visanne) with endometriosis. [Bezopasnost’ dlitel’nogo primeneniya dienogesta (vizanna) pri endometrioze]. Medicinskij alfavit. 2017;1(3):12–5. (In Russ.).
10. Buggio L., Somigliana E., Barbara G. et al. Oral and depot progestin therapy for endometriosis: towards a personalized medicine. Expert Opin Pharmacother. 2017;18(15):1569–81. DOI: 10.1080/14656566.2017.1381086.
11. Lagana A.S., Vitale S.G., Granese R. et al. Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside. Expert Opin Drug Metab Toxicol. 2017;13(6):593–6. DOI: 10.1080/17425255.2017.1297421.
12. Olina A. A., Meteleva T. A. Experience of prolonged use of dienogest in the treatment of endometriosis. [Opyt dlitel’nogo primeneniya dienogesta v terapii endometrioza]. Akusherstvo i ginekologiya. v 2018;(7):97–102. (In Russ.). DOI: 10.18565/aig.2018.7.97-102.
13. Romer T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstet. 2018;298(4):747–53. DOI: 10.1007/s00404-018-4864-8.
14. Lee K.H., Jung Y.W., Song S.Y. et al. Comparison of the efficacy of diegnogest and levonorgestrel-releasing intrauterine system after laparoscopic surgery for endometriosis. J Obstet Gynaecol Res. 2018;44(9):1779–86. DOI: 10.1111/jog.13703.
15. Kim S. A., Um M. J., Kim H. K. et al. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet Gynecol Sci. 2016;59(6):506–11. DOI: 10.5468/ogs.2016.59.6.506.
16. Higham J. M., O’Brien P.M.S., Shaw R. W. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734–39. DOI: 10.1111/j.1471-0528.1990.tb16249.x.
Review
For citations:
Dobrokhotova J.E., Kalimatova D.M., Ilyina I.Yu. Postoperative management of patients with endometriosis. Obstetrics, Gynecology and Reproduction. 2020;14(2):182-191. (In Russ.) https://doi.org/10.17749/2313-7347/ob.gyn.rep.2020.099
Views: 805
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
